Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations
- Details
- Category: Clinical Trials
Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test
- Details
- Category: Abbott
Abbott has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements. Pfizer has developed a novel investigational agent that selectively targets cancer-causing genes implicated in the progress of many cancers.
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received approval from Health Canada for the XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD). XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Lilly Reports on Outcome of Phase III Study of Arzoxifene
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has announced that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene failed to demonstrate a statistically significant difference in key secondary efficacy endpoints, such as non-vertebral fractures, clinical vertebral fractures, cardiovascular events and cognitive function, compared to placebo.
Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
- Details
- Category: Novartis
Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara® (letrozole) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive).
Nycomed reports sustained momentum in second quarter 2009
- Details
- Category: Nycomed
Nycomed reports sustained momentum in the second quarter 2009, with total net turnover increasing by 0.5% to €786.9 million excluding the impact of the Sepracor execution payment received in the first half of 2008. This performance is driven by Nycomed's Key Products. Pantoprazole turnover in Europe dropped only moderately after loosing patent protection in May.
More Pharma News ...
- Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research
- US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis
- Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
- Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab)
- Pandemic (H1N1) 2009 influenza update
- Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
- Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Next Generation Anti-Infective